Qiagen 品牌簡介
QIAGEN was founded 1984 as a spin-off at the University of Düsseldorf. Since then the company has continuously developed and turned into what is today the world's leading provider for innovative sample and assay technologies for research in molecular diagnostics, applied testing, pharma and academic research.
| 2011 |
- QIAGEN acquires a strategic stake in Alacris Theranostics GmbH. The startup uses a novel approach to personalize cancer treatments;
QIAGEN has an exclusive option to commercialize all biomarkers emerging from this research work. |
| 2010 |
- QIAGEN acquires a new detection technology for point of need applications in molecular diagnostics and applied testing. The instruments are highly affordable, portable and generate results in between 5 and 15 minutes.
- This technology plays a key role in a pilot project run by the UN Food and Agriculture Organization and the International Atomic Energy Agency to contain animal diseases in emerging countries.
- QIAGEN launches QIAsymphony RGQ, a modular automation platform covering entire laboratory workflows in molecular diagnostics. Its users have access to the broadest commercially available PCR test portfolio and can also run lab-developed tests.
|
| 2009 |
- QIAGEN’s shares are included in the renowned NASDAQ-100 index.
- QIAGEN enhances its portfolio with several PCR-based assay panels covering entire biological pathways and diseases, thereby strengthening its offering for pharmaceutical research.
- QIAGEN acquires DxS Ltd., creating leadership in personalized healthcare. The combined company is active in more than 15 collaborations with pharmaceutical companies and markets 18 assays for companion diagnostics.
- QIAGEN’s technologies play a key role in the fight against the global Swine Flu pandemic.
- With the real-time PCR cycler Rotor-Gene Q and QIAgility for automated assay setup, QIAGEN enables the automation of complete laboratory workflows from sample to result.
|
| 2008 |
- With Pyrosequencing, QIAGEN acquires a novel detection technology that works on a single base-pair level and thus even allows the identification of unknown DNA sequences or mutations.
- QIAsymphony SP launches as the first system in a series of modular instruments, designed to automate entire laboratory workflows.
|
| 2007 |
- QIAGEN merges with Digene Corp., creating the market and technology leader in molecular diagnostics.
- QIAGEN introduces QIAcube, a revolutionary platform which fully automates the processing of QIAGEN consumable products.
|
| 2006 |
- QIAGEN acquires a “Multiplexing” assay technology, which allows for the testing of multiple pathogens in one single run.
- QIAGEN establishes its Asia regional headquarters in Shanghai.
|
| 2005 |
- QIAGEN acquires a leading position in molecular diagnostics by adding various sets of PCR-based molecular tests to its portfolio.
- Development of the artus influenza kit for the rapid detection of all known variants of the Avian Flu virus H5N1. The test reduces the time to result to 75 minutes.
- QIAGEN receives world’s first governmental clearance for an Avian Flu assay （through its subsidiary PG Biotech in China）.
- QIAGEN launches the first human whole genome siRNA set worldwide. SiRNAs are RNA molecules that can reduce or shut down activity of individual genes for researchers to learn more about their function.
|
| 2004 |
- QIAGEN’s QIAamp becomes the world’s first standalone product for sample preparation to receive the CE mark.
|
| 2002 |
- QIAGEN relocates its US headquarters from Valencia, CA, to Germantown, MD.
|
| 2001 |
- QIAGEN launches PAXgene, the first product that consolidates and integrates key steps of sample collection, stabilization and purification.
|
| 1999 |
- PreAnalytiX, a joint venture with Becton, Dickinson and Company, is established.
|
| 1998 |
- QIAGEN significantly expands its R&D and manufacturing capabilities in the automation business.
|
| 1997 |
- Initial Public Offering is completed on Deutsche Boerse （Prime Standard）, Frankfurt.
|
| 1996 |
- QIAGEN N.V. （Holding） established in Venlo, The Netherlands.
- Initial Public Offering is completed on NASDAQ, New York.
- QIAGEN introduces the BioRobot 9600, its first benchtop workstation, which automates purification technologies.
|
| 1986 |
- QIAGEN revolutionizes molecular biology by introducing the first “Plasmid-Kit.“ The discovery reduces the time needed for the preparation of plasmids, little ring-shaped DNA molecules of a bacteria’s cell, from 2-3 days to 2 hours.
|
| 1984 |
- QIAGEN is founded in Duesseldorf, Germany.
|
手機版
化工儀器網手機版
化工儀器網小程序
官方微信
公眾號：chem17
掃碼關注視頻號
采購中心